Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7801 USD | -7.25% | +17.13% | +39.30% |
04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
04-23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
Sales 2021 | - | Sales 2022 | - | Capitalization | 60.66M 82.92M |
---|---|---|---|---|---|
Net income 2021 | -23M -31.44M | Net income 2022 | -15M -20.5M | EV / Sales 2021 | - |
Net cash position 2021 | 42.19M 57.66M | Net cash position 2022 | 17.76M 24.27M | EV / Sales 2022 | - |
P/E ratio 2021 |
-4.01
x | P/E ratio 2022 |
-3.95
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.56% |
Latest transcript on Tiziana Life Sciences Ltd
1 day | -7.25% | ||
1 week | +17.13% | ||
Current month | +71.83% | ||
1 month | +87.07% | ||
3 months | +39.90% | ||
6 months | +23.83% | ||
Current year | +39.30% |
Managers | Title | Age | Since |
---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 20-06-30 |
Willy Simon
BRD | Director/Board Member | 72 | 15-10-31 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.7801 | -7.25% | 252,821 |
24-04-25 | 0.8411 | +6.45% | 889,692 |
24-04-24 | 0.7901 | +1.95% | 335,885 |
24-04-23 | 0.775 | +2.84% | 2,513,051 |
24-04-22 | 0.7536 | +13.15% | 550,057 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.30% | 78.25M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TLSA Stock